NAD+ had a 93% success rate in a clinical trial of 60 during detox
Intravenous Administration of
Nicotinamide Adenine Dinucleotide
Significantly Reduces Self Reported Craving Ratings Associated With Opiate and Alcohol Withdrawal
Craving Study Introduction
Treatment of substance abuse disorders continues to challenge clinicians and “cravings” for the abused substance are often impediments to sobriety. However, Nicotinamide Adenine Dinucleotide (NAD+) has been used in the past with claims of having anti-craving properties. Previous data from this clinic using a similar formulation of NAD+ support the use of NAD+ as a valid treatment for drug cravings. This pilot study retrospectively examined the anti-craving properties of NAD+ in a group of 60 patients. Additionally, patients were assessed on severity of cravings and relapse episodes at 12-20 months post treatment.
The patients were adult males and females with addictions to primarily opiates or alcohol (N=60). However, six patients had incomplete data. The treatment, Brain Restoration Plus (BR+)TMcomprised of IV infusions of NAD+ as well as vitamins, oral amino acids, NAC and variable PRN medications for an average of 10 consecutive days ranging from 5 to 10 hours daily at a dose range of 500mg-1500mg each day. Self-reported craving ratings (0-10 Scale) came in on Day 1 (before starting treatment), Day 5, and on Day 10 (last day of treatment). Follow up phone surveys were also conducted from 12-20 months post treatment (N= 27). Patients reported severity of cravings (1-5) and number of relapse episodes at the present time.
NAD+ is an effective detox treatment for alcohol as well as opiate addicts as evidenced by a significant reduction in craving ratings. On top of this, NAD+ was effective in reducing and maintaining the number of relapse episodes, as well as severity of drug cravings. NAD+ shows potential as a long-term therapy in maintaining sobriety through minimizing drug cravings and also preventing relapse.
Regarding citations for the comparison chart, effectiveness depends upon how success is measured (completion of the program, NO subsequent drug use, REDUCED subsequent drug use, as well as no subsequent criminal activity, etc.), and also the profile of the patient (homeless addicts may do better in a residential program because it addresses two problems at once; people with dual-diagnosis may require psychiatric hospitalization, etc.). However the following three citations present a rational that may be helpful:
40%-60% of all (conventional) (inpatient, outpatient, hospital) rehab patients relapse according to the NIH’s National Institute on Drug Abuse.
Long-term drug use results in changes in the brain that persist long after a person stops using drugs. These drug-induced changes in brain function include an inability to exert control over the impulse to use drugs despite adverse consequences—the defining characteristic